Login to Your Account

Pivotal trial Evoke's failure for diabetic gastroparesis drug

By Michael Fitzhugh
Staff Writer

Monday, July 18, 2016

A missed endpoint in the pivotal trial of its sole candidate sent shares of Evoke Pharma Inc. down 73.1 percent Monday as the company's nasal formulation of the proven diabetic gastroparesis drug metoclopramide failed to achieve its primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription